Close Menu

NEW YORK (GenomeWeb) – Sample prep firm Ceres Nanosciences aims to raise $5 million in equity funding this summer to support further commercialization of its urine-based Lyme disease diagnostic.

The company is currently in discussions with several investor groups, CEO Ross Dunlap told GenomeWeb, and plans to use the funds to expand the reach of the test, which it currently offers on a limited, clinical study basis through George Mason University's CLIA laboratory and several private clinics in the Northern Virginia area.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers have used CRISPR-Cas9 to efficiently target a cephalopod pigmentation gene, as they report in Current Biology.

According to the Wall Street Journal, the Food and Drug Administration may soon issue an Emergency Use Authorization for convalescent plasma to treat COVID-19 patients.

Minnesota police have used genetic genealogy to make an arrest in a 1986 cold case, reports NBC News.

In Science this week: chromatin accessibility of microglia during fetal development, and more.

Sep
09
Sponsored by
10x Genomics

Recent advances in spatially resolved transcriptomics have greatly expanded the knowledge of complex multicellular biological systems.